Answers are grounded in this paper and cite their sources.
Prospective evaluation shows effective response in pediatric Crohn's disease, indicating a viable treatment option.
Weekly 80 mg adalimumab appears to be an effective and well-tolerated intensification strategy in pediatric CD patients with pharmacokinetic loss of response. Further prospective studies are needed to confirm these findings and guide optimal use.
No takes yet. Share an insight, caveat, or question.
Cohen‐Sela et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: